PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma-Reference-Cited by-同舟云学术

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

Published:2005-06 Issue:6 Volume:129 Page:755-762
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Oakervee Heather E.,Popat Rakesh,Curry Nicola,Smith Pat,Morris Curly,Drake Mary,Agrawal Samir,Stec Jim,Schenkein David,Esseltine Dixie-Lee,Cavenagh Jamie D.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2005.05519.x/fullpdf

Reference38 articles.

1. The proteasome: a suitable antineoplastic target

2. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

3. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

4. Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Cited by 285 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes of myocardial dysfunction and injury biomarkers over chemotherapy for multiple myeloma: difficulties in laboratory data interpretation;Rational Pharmacotherapy in Cardiology;2023-11-07

2. Cellular immunity in the era of modern multiple myeloma therapy;International Journal of Cancer;2023-06-12

3. Targeted therapy;Medicines for Cancer;2023

4. Myeloma and Leukemia;Oncologic Imaging : a Multidisciplinary Approach;2023

5. Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow;Toxicological Sciences;2022-07-13